文献速递胸部CT

肺癌筛查合格人群中肺功能保留的间质性肺异常:对肺功能与预后的长期影响

Interstitial lung abnormality with preserved pulmonary function in lung cancer screening-eligible individuals: long-term effects on function and prognosis.
PubMed 文献 · Eur Radiol · 2025-07-26

该回顾性研究纳入2012至2014年体检中符合2021年美国预防服务工作组肺癌筛查标准的连续参与者,分析基线用力肺活量≥80%且随访有CT和肺功能数据的133例。CT进展见于81.8%的间质性肺异常者和67.2%的可疑间质性肺异常者,CT进展与用力肺活量降至80%以下无关,但是死亡的独立危险因素(HR 8.74),相对用力肺活量下降≥10%亦为独立危险因素(HR 10.30)。

要点

  • 间质性肺异常者CT进展率81.8%(54/66),可疑间质性肺异常者67.2%(45/67)。
  • CT进展与用力肺活量降至80%以下无关(p=0.720),仅基线用力肺活量与之相关(HR 0.78)。
  • CT进展(HR 8.74)和相对用力肺活量下降≥10%(HR 10.30)是死亡的独立危险因素。

核心结论

  • 在肺功能保留的肺癌筛查参与者中,CT进展是死亡的危险因素,但与用力肺活量降至80%以下无关;监测CT进展有助于间质性肺异常参与者的风险分层。

研究设计与样本

  • 回顾性分析2012至2014年体检中符合2021年美国预防服务工作组肺癌筛查标准的连续参与者,共6332例,最终纳入133例基线用力肺活量≥80%且有随访CT和肺功能数据者。

关键影像表现/征象

  • CT进展见于81.8%(54/66)的间质性肺异常者和67.2%(45/67)的可疑间质性肺异常者,中位随访分别为61.0个月和76.0个月。
  • 用力肺活量降至80%以下见于21.1%(28/133),中位时间61.4个月。

诊断标准与关键数值

  • 基线用力肺活量≥80%定义为肺功能保留。
  • 用力肺活量降至80%以下仅与基线用力肺活量相关(HR 0.78,p<0.001),与CT进展(p=0.720)和纤维化型间质性肺异常(p=0.066)无关。
  • 死亡与CT进展(HR 8.74,p<0.001)和相对用力肺活量下降≥10%(HR 10.30,p<0.001)独立相关,与纤维化型间质性肺异常无关(p=0.254)。

临床应用与阅片要点

  • 在肺癌筛查随访中监测间质性肺异常的CT进展,可能有助于对间质性肺异常参与者进行风险分层。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVES: To evaluate the effect of CT progression of interstitial lung abnormality (ILA) and ILA subtypes on pulmonary function and mortality in lung cancer screening (LCS) participants with preserved pulmonary function.

MATERIALS AND METHODS: Consecutive participants who met the 2021 United States Preventive Services Task Force guidelines for LCS during a medical check-up between 2012 and 2014 were retrospectively analyzed. Forced vital capacity (FVC) ≥ 80% at baseline was considered indicative of preserved pulmonary function. CT progression and ILA subtype were evaluated for their association with an FVC decline to < 80% and mortality using multivariable time-dependent Cox analysis.

RESULTS: Among the 6332 LCS participants, 133 with baseline FVC ≥ 80% and follow-up CT and FVC data were included. CT progression was observed in 81.8% (54/66) of those with ILA and 67.2% (45/67) of those with equivocal ILA, with median follow-ups of 61.0 and 76.0 months, respectively. FVC decline to < 80% occurred in 21.1% (28/133) with a median time of 61.4 months. It was associated only with baseline FVC (hazard ratio (HR), 0.78; p < 0.001), while CT progression (p = 0.720) and fibrotic ILA (p = 0.066) were not. For mortality, both CT progression (HR, 8.74; p < 0.001) and a relative FVC decline ≥ 10% (HR, 10.30; p < 0.001) were independent risk factors, whereas fibrotic ILA was not (p = 0.254).

CONCLUSION: CT progression was a risk factor for mortality, although it was not associated with a decline in FVC to below 80% in participants with preserved lung function. Monitoring CT progression in LCS would be helpful for risk stratification of participants with ILA.

KEY POINTS: Question Does interstitial lung abnormality (ILA) CT progression affect pulmonary function decline and mortality, even when pulmonary function is preserved? Findings When pulmonary function was preserved, CT progression was not associated with forced vital capacity decline but was an independent risk factor for mortality. Clinical relevance Monitoring CT progression during lung cancer screening adherence could aid in risk stratification for participants with ILA.

来源:Eur Radiol,查看原文。版权归原作者所有。

引用

  1. Ahn Y, Lee SM, Choe J, et al. Interstitial lung abnormality with preserved pulmonary function in lung cancer screening-eligible individuals: long-term effects on function and prognosis. Eur Radiol. 2025. PMID: 40715650. doi:10.1007/s00330-025-11874-w

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。